Back to today’s briefing

Story perspectives

Yuflyma Gains FDA Approval, Set to Disrupt U.S. Market

4/15/2025

50 6

Summary

Story summary

Celltrion's biosimilar Yuflyma has just gained U.S. FDA approval, paving the way for it to replace Humira without the need for prescriptions. This milestone is set to elevate Yuflyma's presence in the U.S. market. In Europe, biosimilars are revolutionizing the generic drug landscape, making healthcare more affordable and benefiting countless patients and healthcare providers alike.

1 of 1

Story summary

Celltrion's biosimilar Yuflyma has just gained U.S. FDA approval, paving the way for it to replace Humira without the need for prescriptions. This milestone is set to elevate Yuflyma's presence in the U.S. market. In Europe, biosimilars are revolutionizing the generic drug landscape, making healthcare more affordable and benefiting countless patients and healthcare providers alike.